Senti Biosciences Holdings, Inc. (SNTI) stock
SNTINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.10−0.04 (-28.68%)
Close on Nov 17, 2026Market cap $3.02MP/E –Yield –
Senti Biosciences profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Senti Biosciences's profit margin for the twelve months ending Jun 30, 2024 was -32335.8%. For fiscal 2025 it was -279263.6%, against -2774.6% the year before.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -279263.6% | −276489.0 |
| FY2023 | Dec 31, 2023 | -2774.6% | −1416.5 |
| FY2022 | Dec 31, 2022 | -1358.1% | +645.4 |
| FY2021 | Dec 31, 2021 | -2003.6% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -75000.0% | −73544.2 |
| Q1 FY2026 | Mar 31, 2026 | -26381.3% | +72279.8 |
| Q3 FY2023 | Sep 30, 2023 | -4415.1% | −3472.8 |
| Q2 FY2023 | Jun 30, 2023 | -1995.4% | −1144.7 |
| Q1 FY2023 | Mar 31, 2023 | -1455.8% | −386.3 |
| Q4 FY2022 | Dec 31, 2022 | -98661.0% | −97286.0 |
| Q3 FY2022 | Sep 30, 2022 | -942.2% | +91.8 |
| Q2 FY2022 | Jun 30, 2022 | -850.7% | +663.5 |
| Q1 FY2022 | Mar 31, 2022 | -1069.6% | – |
| Q4 FY2021 | Dec 31, 2021 | -1375.0% | – |
| Q3 FY2021 | Sep 30, 2021 | -1034.1% | – |
| Q2 FY2021 | Jun 30, 2021 | -1514.1% | – |
See a number that looks wrong?